Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed · Phase 3

Conditions studied: Hepatitis C

In brief

The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated Interferon Alfa-2a + Ribavirin + Telaprevir in subjects who are infected with Chronic Hepatitis C virus genotype 1b and have never received any prior anti-HCV treatment, or who have relapsed after an initial, successful treatment with Pegylated Interferon Alfa + Ribavirin

Key facts

Study ID

NCT01718158

Run by

Bristol-Myers Squibb

People needed

444

Starts

2013-01-01

Expected to finish

2014-10-01

Last updated by the study team

2015-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients chronically infected with HCV Genotype-1b
• Naïve to prior treatment or documented evidence of relapse after completion of the prescribed duration of treatment (duration may be 24 or 48 weeks, to be determined based upon local guidelines)
• HCV RNA viral load ≥100,000 IU/mL at screening
• Patients with compensated cirrhosis are permitted

You may not qualify if…

• Infection with Hepatitis C virus (HCV) other than Genotype-1b
• Positive Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus (HIV)-1/HIV-2 antibody test at screening
• Evidence of chronic liver disease caused by diseases other than chronic HCV infection
• Current evidence of or history of variceal bleeding, hepatic encephalopathy, or ascites requiring diuretics or paracentesis or evidence of any of these findings on physical examination performed at screening
• Current or known history of cancer (except adequately treated in situ carcinoma of the cervix, or basal or squamous cell carcinoma of the skin) within 5 years prior to screening
• Current evidence or known history of decompensated cirrhosis based on radiologic criteria or biopsy results and clinical criteria
• Laboratory values:
• Hemoglobin <12.0 g/dL (males) or <11.0 g/dL (females)
• Platelets <90,000/mm3
• Total serum bilirubin ≥2 mg/dL (unless due to Gilbert's disease)

Where it is running

• Gastrointestinal Specialists Of Georgia Pc — Marietta, Georgia, United States
• Weill Cornell Medical College — New York, New York, United States
• Premier Medical Group Of The Hudson Valley, Pc — Poughkeepsie, New York, United States
• Lehigh Valley Health Network — Allentown, Pennsylvania, United States
• Nashville Medical Research Institute — Nashville, Tennessee, United States
• Texas Clinical Research Institute, Llc — Arlington, Texas, United States
• Medvamc — Houston, Texas, United States
• Local Institution — Buenos Aires, Buenos Aires, Argentina
• Local Institution — Buenos Aires, Buenos Aires, Argentina
• Local Institution — Buenos Aires, Buenos Aires, Argentina
• Local Institution — Capital Federal, Buenos Aires, Argentina
• Local Institution — Mar del Plata, Buenos Aires, Argentina
• Local Institution — Prov de Santa Fe, Santa Fe Province, Argentina
• Local Institution — Clichy, France
• Local Institution — Grenoble, France
• Local Institution — Villejuif, France
• Local Institution — Berlin, Germany
• Local Institution — Essen, Germany
• Local Institution — Hamburg, Germany
• Local Institution — Mannheim, Germany
• Local Institution — München, Germany
• Local Institution — Haifa, Israel
• Local Institution — Tel Aviv, Israel
• Local Institution — Tel Litwinsky, Israel
• Va Long Beach Healthcare System — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.